The uptake of injectable obesity drugs like semaglutide, tirzepatide, and liraglutide has been high, and the new wave of oral medications promises even greater adoption. The availability of effective weight loss drugs is having a tremendous positive impact for patients with obesity worldwide.

The clinical development pipeline remains rich, including compounds that target additional mechanisms for weight loss and reducing nausea. This is both good and bad news for pharma companies—there is a lucrative market and high demand for new treatments, but also intense competition.

In this webinar, our Chief Science Officer of QSP, Dr. Scott Q. Siler, will discuss how quantitative systems pharmacology (QSP) can increase the efficiency of clinical development efforts.

Using the OBESITYsym model, Scott will show you how to simultaneously predict weight loss and nausea for a given treatment in a simulated population of patients with obesity. While the original model was calibrated and validated with numerous compounds, including the injectable drugs on market, it has since been expanded to include the two oral drugs currently available to patients, semaglutide and orforglipron, and drugs with additional mechanistic components, such as the GLP1-GIP-GLP triple agonist, retatrutide. Attendees will get a first look at how these updates provide a competitive edge, and have a chance to get questions answered in real-time during the Q&A.

If you’re developing an obesity drug, this is a webinar you won’t want to miss.